Tenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial

MT Newswires Live03-24

Tenaya Therapeutics (TNYA) said Monday that preclinical data for TN-201, its gene therapy candidate for myosin-binding protein C3-associated hypertrophic cardiomyopathy, showed improved heart function.

Published preclinical data also showed extended survival and lower cardiac biomarkers associated with fibrosis and heart failure, the company said.

A mouse surrogate of TN-201 was tested against vehicle in a model that mimics severe disease in humans, Tenaya said.

The company said the results, which were dose-dependent and lasted 20 months after treatment, support its clinical development plan for TN-201. Tenaya is conducting a phase 1b/2 clinical trial to assess TN-201 as a potential treatment for myosin-binding protein C3-associated hypertrophic cardiomyopathy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2521721364?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-24 21:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521721364","market":"hk","top_or_hot":-1,"title":"Tenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial","media":"MT Newswires Live","content":"<html><body><p> Tenaya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TNYA) said Monday that preclinical data for TN-201, its gene therapy candidate for myosin-binding protein C3-associated hypertrophic cardiomyopathy, showed improved heart function.</p><p>Published preclinical data also showed extended survival and lower cardiac biomarkers associated with fibrosis and heart failure, the company said.</p><p>A mouse surrogate of TN-201 was tested against vehicle in a model that mimics severe disease in humans, Tenaya said.</p><p>The company said the results, which were dose-dependent and lasted 20 months after treatment, support its clinical development plan for TN-201. Tenaya is conducting a phase 1b/2 clinical trial to assess TN-201 as a potential treatment for myosin-binding protein C3-associated hypertrophic cardiomyopathy.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-24 21:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Tenaya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TNYA) said Monday that preclinical data for TN-201, its gene therapy candidate for myosin-binding protein C3-associated hypertrophic cardiomyopathy, showed improved heart function.</p><p>Published preclinical data also showed extended survival and lower cardiac biomarkers associated with fibrosis and heart failure, the company said.</p><p>A mouse surrogate of TN-201 was tested against vehicle in a model that mimics severe disease in humans, Tenaya said.</p><p>The company said the results, which were dose-dependent and lasted 20 months after treatment, support its clinical development plan for TN-201. Tenaya is conducting a phase 1b/2 clinical trial to assess TN-201 as a potential treatment for myosin-binding protein C3-associated hypertrophic cardiomyopathy.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2521721364","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521721364","pubTimestamp":1742822571,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tenaya Therapeutics  said Monday that preclinical data for TN-201, its gene therapy candidate for myosin-binding protein C3-associated hypertrophic cardiomyopathy, showed improved heart function.Published preclinical data also showed extended survival and lower cardiac biomarkers associated with fibrosis and heart failure, the company said.A mouse surrogate of TN-201 was tested against vehicle in a model that mimics severe disease in humans, Tenaya said.The company said the results, which were dose-dependent and lasted 20 months after treatment, support its clinical development plan for TN-201. Tenaya is conducting a phase 1b/2 clinical trial to assess TN-201 as a potential treatment for myosin-binding protein C3-associated hypertrophic cardiomyopathy.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","TNYA":"Tenaya Therapeutics Inc","BK4539":"次新股"},"translate_title":"Tenaya Therapeutics表示候选基因疗法在临床前试验中可改善心脏功能","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"TNYA":1},"content_text":"Tenaya Therapeutics (TNYA) said Monday that preclinical data for TN-201, its gene therapy candidate for myosin-binding protein C3-associated hypertrophic cardiomyopathy, showed improved heart function.Published preclinical data also showed extended survival and lower cardiac biomarkers associated with fibrosis and heart failure, the company said.A mouse surrogate of TN-201 was tested against vehicle in a model that mimics severe disease in humans, Tenaya said.The company said the results, which were dose-dependent and lasted 20 months after treatment, support its clinical development plan for TN-201. Tenaya is conducting a phase 1b/2 clinical trial to assess TN-201 as a potential treatment for myosin-binding protein C3-associated hypertrophic cardiomyopathy.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2521721364"}